Dermatology

Continuous secukinumab treatment showed sustained hidradenitis suppurativa lesion control through 4 years in responding patients.

Remibrutinib improved itch and hive severity within 12 hours in chronic spontaneous urticaria in Phase III analysis.

Serum sickness after botulinum toxin type A may signal a rare delayed systemic immune reaction. Read more.

Microneedle patches may improve hyperpigmentation treatment by enhancing skin delivery, efficacy, and tolerability of active agents.

Definisse KP1 eye contour cream may enhance eye rejuvenation when combined with onabotulinum toxin A. Read more.

Fractional CO2 laser improved post-acne scars more than microneedling radiofrequency, but with greater pain and downtime.

Delgocitinib cream significantly improved quality of life in adults with moderate to severe Chronic Hand Eczema (CHE) in pooled phase III trial data.

Abrocitinib appears durable and well tolerated in patients with moderate-to-severe atopic dermatitis (AD), also known as eczema, according to a 2-year retrospective real-world study.